Literature DB >> 12082615

Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function.

Mark Morris1, Peter Hepburn, David Wynford-Thomas.   

Abstract

Replicative senescence is thought to be a significant barrier to human tumorigenesis, which in human fibroblasts, and many other cell types, can be overcome experimentally by combined loss of function of p53 and Rb 'pathways'. To avoid the confounding pleiotropic effects of HPVE7 frequently used in such studies, here we have employed retroviral vectors over-expressing CDK4 or CDK6 as a more representative model of naturally-occurring mutations targeting the Rb pathway. We show that these can extend fibroblast lifespan by approximately 10 population doublings, ending in a viable senescence-like state which contrasts with the apoptotic end-stage seen with E7. Compared with 'normal' senescence, this growth arrest was, in most cases, not accompanied by any further increase in p21(Waf1) levels but with up to a 19-fold increase in p16(Ink4a). Surprisingly however, this could not explain arrest, since expression of mutant CDK4 and/or CDK6, incapable of binding p16(Ink4a), did not confer any greater lifespan extension than the wild-type CDKs. Subsequent abrogation of p53 function by a second vector, encoding HPVE6, downregulated p21(Waf1) and conferred a second lifespan extension, ending in a crisis-like state, consistent with full escape from senescence. These data: (i) point to a back-up 'senescence' mechanism distinct from induction of p21(Waf1) or p16(Ink4a); and (ii) provide an in vitro model of clonal evolution through successive dysfunction of Rb and p53 pathways in a relevant human cell context.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082615     DOI: 10.1038/sj.onc.1205492

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Cell senescence and hypermitogenic arrest.

Authors:  Mikhail V Blagosklonny
Journal:  EMBO Rep       Date:  2003-04       Impact factor: 8.807

2.  Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts.

Authors:  Wenyi Wei; Wendy A Jobling; Wen Chen; William C Hahn; John M Sedivy
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

3.  Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins.

Authors:  Eriko Michishita; Jean Y Park; Jenna M Burneskis; J Carl Barrett; Izumi Horikawa
Journal:  Mol Biol Cell       Date:  2005-08-03       Impact factor: 4.138

4.  Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts.

Authors:  Wenyi Wei; Utz Herbig; Shan Wei; Annie Dutriaux; John M Sedivy
Journal:  EMBO Rep       Date:  2003-10-17       Impact factor: 8.807

5.  Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts.

Authors:  Kristin E Yates; Gregory A Korbel; Michael Shtutman; Igor B Roninson; Daniel DiMaio
Journal:  Aging Cell       Date:  2008-07-24       Impact factor: 9.304

6.  CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.

Authors:  Margarida Ruas; Fiona Gregory; Rebecca Jones; Robert Poolman; Maria Starborg; Janice Rowe; Sharon Brookes; Gordon Peters
Journal:  Mol Cell Biol       Date:  2007-04-09       Impact factor: 4.272

7.  Enhanced malignant tumorigenesis in Cdk4 transgenic mice.

Authors:  Paula L Miliani de Marval; Everardo Macias; Claudio J Conti; Marcelo L Rodriguez-Puebla
Journal:  Oncogene       Date:  2004-03-11       Impact factor: 9.867

8.  p16INK4a-induced senescence is disabled by melanoma-associated mutations.

Authors:  Sebastian Haferkamp; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging Cell       Date:  2008-10       Impact factor: 9.304

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.